Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 ...

Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.’ This study aims to assess the safety and efficacy of ritlecitinib, a potential treatment for ...

More than half of adolescents treated with baricitinib achieved complete or near-complete scalp hair regrowth at 1 year, with ...

The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata. The Food and Drug Administration (FDA) has approved ...

Forte Biosciences Inc. (($FBRX)) announced an update on their ongoing clinical study. Forte Biosciences Inc. is conducting a study titled ‘A ...

New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped ...

People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study. A post hoc study conducted in adults with ...

For Christian Daniels, it started when his co-worker pointed out a dime-sized bald patch on the back of his head. Within days, he was waking up each morning to find clumps of hair on his white ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

Please provide your email address to receive an email when new articles are posted on . By week 152, 80% of patients who were withdrawn from baricitinib therapy lost their hair again vs. only 7% of ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...